Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole (BMS)
Schizophrenia, Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Obesity, Hyperglycemia, Dyslipidemia, Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria: Patient meets DSM-IV criteria for Schizophrenia 18-60 years of age or older Able to give informed consent Treated with olanzapine, quetiapine, risperidone or ziprasidone for greater than or equal to 3 months prior to enrollment Exclusion Criteria: pregnant or breastfeeding women will be excluded Meets DSM-IV criteria for substance abuse or dependence within past 6 months involuntary legal status (as per Missouri law) any serious medical disorder that may confound assessment of symptoms subjects taking prescription medications except psychotropic meds meets DSM-IV criteria for Mental Retardation (mild or worse) Subjects taking tricyclic antidepressants or mood stabilizers
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Other
Other
Stayers
Switchers
Subjects are randomized to stay on their current antipsychotic.
Subjects are randomized to switch to aripiprazole from their current antipsychotic.